Are depot anti-psychotics associated with longer persistence in treatment compared with oral antipsychotics among patients with schizophrenia?

Are depot anti-psychotics associated with longer persistence in treatment compared with oral antipsychotics among patients with schizophrenia?

Author by Dr. Increase Adeosun

Journal/Publisher: Journal Of Pharmaceutical Research International

Volume/Edition: 18

Language: English

Pages: 1 - 8

Abstract

Aim: Non-adherence with antipsychotics is associated with poor outcomes in patients with

schizophrenia. It was anticipated that drop-out from treatment due to non-compliance with oral antipsychotics

could be abated with the use of depot antipsychotics. However previous studies are

divergent regarding the association between persistence in treatment and the use of depot

antipsychotics. This study aimed to compare treatment persistence among out-patients with

schizophrenia receiving depot versus oral antipsychotics in Lagos, Nigeria.

Methodology: Relevant clinical data of out-patients with schizophrenia (n=160) were retrieved one

year post-hospitalisation at a public psychiatric facility in Nigeria. Treatment persistence (time to all

cause treatment discontinuation) among the cohort of patients was determined using the Kaplan-

Meier Survival analyses. Persistence in treatment between patients receiving depot versus oral

antipsychotic medications alone was compared using the log rank test.

Results: Nearly half (49.1%) of the cohort dropped out of treatment within one month of discharge,

while 18.2% persisted for one year. There was no significant difference (p=0.727) in the mean

duration of treatment persistence between patients receiving depot antipsychotics (17.4(±2.4)

weeks), and those receiving oral medications alone (19.4 (±2.2) weeks)

 Conclusion: There is a high rate of drop-out from treatment among patients with schizophrenia,

after discharge from in-patient care. Prescription of depot medications was not associated with

longer persistence treatment in the studied cohort. This finding highlights the need to develop

interventions to facilitate treatment persistence among patients with schizophrenia


Other Co-Authors